HeartSciences (NASDAQ:HSCS) Releases Quarterly Earnings Results

Posted by Brenda Bartman on Jul 25th, 2026

HeartSciences (NASDAQ:HSCS – Get Free Report) posted its earnings results on Thursday. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.22), Zacks reports.

HeartSciences Stock Down 2.0%

HSCS stock opened at $2.39 on Friday. The stock has a fifty day moving average of $2.27 and a 200-day moving average of $2.50. HeartSciences has a fifty-two week low of $1.63 and a fifty-two week high of $4.30. The company has a market capitalization of $7.60 million, a price-to-earnings ratio of -0.61 and a beta of 1.78. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.04 and a current ratio of 1.19.

Hedge Funds Weigh In On HeartSciences

An institutional investor recently raised its stake in HeartSciences stock. DRW Securities LLC grew its holdings in HeartSciences Inc. (NASDAQ:HSCS – Free Report) by 13.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 95,065 shares of the company’s stock after purchasing an additional 11,455 shares during the period. DRW Securities LLC owned approximately 2.99% of HeartSciences worth $294,000 at the end of the most recent quarter. 17.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, HeartSciences has an average rating of “Hold” and an average target price of $8.00.

Get Our Latest Stock Report on HSCS

HeartSciences Company Profile

(Get Free Report)

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.